| The treatment of incomplete data: reporting, analysis, reproducibility, and replicability Y Sidi, O Harel Social Science & Medicine 209, 169-173, 2018 | 118 | 2018 |
| GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with … JS Wolinsky, TE Borresen, DW Dietrich, D Wynn, Y Sidi, JR Steinerman, ... Multiple sclerosis and related disorders 4 (4), 370-376, 2015 | 74 | 2015 |
| Long‐term effects of rasagiline and the natural history of treated Parkinson's disease O Rascol, RA Hauser, F Stocchi, CJ Fitzer‐Attas, Y Sidi, V Abler, ... Movement Disorders 31 (10), 1489-1496, 2016 | 54 | 2016 |
| The relationship between brain MR spectroscopy and disability in multiple sclerosis: 20‐year data from the US glatiramer acetate extension study O Khan, N Seraji‐Bozorgzad, F Bao, S Razmjou, C Caon, C Santiago, ... Journal of Neuroimaging 27 (1), 97-106, 2017 | 27 | 2017 |
| 651O Pembrolizumab (pembro)+ carboplatin (carbo)+ paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC … MR Dzienis, JE Cundom, CS Fuentes, AR Hansen, MJ Nordlinger, ... Annals of Oncology 33, S839-S840, 2022 | 13 | 2022 |
| GLACIER: An Open-label, Randomized, Multicenter Study to Assess Safety and Tolerability of Glatiramer Acetate 40 mg/1mL 3-times Weekly Versus 20 mg/1mL Daily in Patients with … W Jerry, T Borresen, D Dietrich, B Gilder, Y Sidi, V Knappertz, S Kolodny Neurology 82 (10_supplement), S31. 002, 2014 | 4 | 2014 |
| Mediation of the Effect of Laquinimod on Disability Progression in Relapsing-Remitting Multiple Sclerosis (RRMS)(P3. 195) G Comi, D Ladkani, T Vollmer, MP Sormani, Y Sidi, V Knappertz Neurology 82 (10_supplement), P3. 195, 2014 | 4 | 2014 |
| Cost analysis of alpha blocker treatments for benign prostatic hyperplasia in Medicare beneficiaries Y Sidi, Y Duan, TG Rhee, ZH Wu Research in Social and Administrative Pharmacy 17 (6), 1119-1139, 2021 | 3 | 2021 |
| Comprehensive benefit–risk assessment of noninferior treatments using multicriteria decision analysis Y Sidi, O Harel Value in Health 23 (12), 1622-1629, 2020 | 3 | 2020 |
| Difference between binomial proportions using Newcombe’s method with multiple imputation for incomplete data Y Sidi, O Harel The American Statistician 76 (1), 29-36, 2022 | 2 | 2022 |
| Noninferiority Clinical Trials With Binary Outcome: Statistical Methods Used in Practice Y Sidi, O Harel Statistics in Biopharmaceutical Research 13 (4), 476-482, 2021 | 2 | 2021 |
| GLACIER: open-label, randomized safety/tolerability study of glatiramer acetate 40mg/mL three times weekly versus 20mg/mL daily in RRMS JS Wolinsky, DW Dietrich, TE Borresen, BF Gilder, JR Steinerman, Y Sidi, ... MULTIPLE SCLEROSIS JOURNAL 20, 43-44, 2014 | 2 | 2014 |
| Safety and Tolerability of Escalating Doses of Laquinimod, an Oral Immunomodulatory Agent in Development for Treatment of Relapsing-Remitting Multiple Sclerosis (P2. 205) H Tumani, T Ziemssen, F Paul, M Marziniak, N Richter, C Heesen, ... Neurology 82 (10_supplement), P2. 205, 2014 | 2 | 2014 |
| Results of switching to laquinimod in the open-label extension phase of the BRAVO study T Vollmer, PS Sorensen, K Selmaj, F Zipp, E Havrdova, J Cohen, Y Sidi, ... MULTIPLE SCLEROSIS JOURNAL 19 (11), 489-489, 2013 | 2 | 2013 |
| Predicting brain volume loss at two years as a function of MRI activity in the first year with laquinimod M Rocca, G Comi, D Jeffery, L Kappos, X Montalban, A Boyko, T Gorfine, ... MULTIPLE SCLEROSIS JOURNAL 19 (11), 131-132, 2013 | 2 | 2013 |
| Incomplete data analysis of non-inferiority clinical trials: Difference between binomial proportions case Y Sidi, O Harel Contemporary Clinical Trials Communications 18, 100567, 2020 | 1 | 2020 |
| Switching from interferon beta-1a IM to laquinimod: safety and efficacy results from the BRAVO study extension TL Vollmer, N Ashtamker, Y Sidi, D Ladkani, T Gorfine, PS Sorensen MULTIPLE SCLEROSIS JOURNAL 20, 91-91, 2014 | 1 | 2014 |
| Laquinimod effect on confirmed disability progression: minimal mediation by relapse or T2 lesions reduction MP Sormani, TL Vollmer, G Comi, Y Sidi, JR Steinerman, T Gorfine, ... MULTIPLE SCLEROSIS JOURNAL 20, 98-98, 2014 | 1 | 2014 |
| Convenience of glatiramer acetate 40mg/mL three times weekly: evidence from the GLACIER study JS Wolinsky, TE Borresen, DW Dietrich, BF Gilder, Y Sidi, JR Steinerman, ... MULTIPLE SCLEROSIS JOURNAL 20, 103-103, 2014 | 1 | 2014 |
| Reduced frequency and severity of injection site reactions with glatiramer acetate 40mg/mL three times weekly dosing JS Wolinsky, Y Sidi, JR Steinerman, V Knappertz, S Kolodny MULTIPLE SCLEROSIS JOURNAL 20, 203-204, 2014 | 1 | 2014 |
